Intellia Therapeutics Inc (NTLA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Intellia Therapeutics Inc (NTLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8125
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intellia Therapeutics Inc (Intellia Therapeutics) is a genome editing company that develops proprietary curative therapeutics using CRISPR/Cas9 technology. The company develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, hepatitis B infection, inborn errors of metabolism and primary hyperoxaluria. It also develops ex vivo programs such as hematopoietic stem cells and chimeric antigen receptor T cells. Intellia Therapeutics conducts genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The company has partnership with various bioscience and pharmaceutical companies to develop its products. Intellia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Intellia Therapeutics Inc (NTLA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Intellia Therapeutics Raises USD70 Million in Series B Financing 12
Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 14
Partnerships 15
Intellia Therapeutics and San Raffaele University and Research Hospital Enter into Research Agreement 15
Licensing Agreements 16
CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 16
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 18
Novartis Enters into Research and Licensing Agreement with Intellia Therapeutics 20
Intellia Therapeutics Amends Licensing Agreement with Caribou Biosciences 21
Equity Offering 22
Intellia Therapeutics Raises USD150 Million in Public Offering of Shares 22
Intellia Therapeutics Raises USD124.4 Million in IPO 24
Intellia Therapeutics Raises USD70 Million in Private Placement of Series B Preferred Stock 26
Intellia Therapeutics Inc – Key Competitors 28
Intellia Therapeutics Inc – Key Employees 29
Intellia Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 01, 2018: Intellia Therapeutics Announces Second Quarter 2018 Financial Results 31
May 01, 2018: Intellia Therapeutics Reports First Quarter 2018 Financial Results 33
Mar 14, 2018: Intellia Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 35
Oct 31, 2017: Intellia Therapeutics Announces Third Quarter 2017 Financial Results 37
Aug 01, 2017: Intellia Therapeutics Announces Second Quarter 2017 Financial Results 39
May 02, 2017: Intellia Therapeutics Announces First Quarter 2017 Financial Results 41
Mar 14, 2017: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results 43
Corporate Communications 46
Dec 18, 2017: Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer 46
Jul 24, 2017: Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee 47
Legal and Regulatory 49
Sep 10, 2018: CRISPR Therapeutics, Intellia Therapeutics & Caribou Biosciences provide update on US federal circuit decision upholding the ruling by US patent and trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology 49
Apr 13, 2017: CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision 50
Product News 51
12/11/2017: Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting 51
05/17/2018: Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting 52
Mar 08, 2017: Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellia Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intellia Therapeutics Raises USD70 Million in Series B Financing 12
Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 14
Intellia Therapeutics and San Raffaele University and Research Hospital Enter into Research Agreement 15
CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 16
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 18
Novartis Enters into Research and Licensing Agreement with Intellia Therapeutics 20
Intellia Therapeutics Amends Licensing Agreement with Caribou Biosciences 21
Intellia Therapeutics Raises USD150 Million in Public Offering of Shares 22
Intellia Therapeutics Raises USD124.4 Million in IPO 24
Intellia Therapeutics Raises USD70 Million in Private Placement of Series B Preferred Stock 26
Intellia Therapeutics Inc, Key Competitors 28
Intellia Therapeutics Inc, Key Employees 29
Intellia Therapeutics Inc, Subsidiaries 30

List of Figures
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Intellia Therapeutics Inc (NTLA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rex International Holding Ltd (5WH):企業の財務・戦略的SWOT分析
    Summary Rex International Holding Ltd (Rex International) formerly Rex International Holding Pte Ltd is an independent exploration and production oil company. The company develops oil and gas properties across Singapore. It operates substantial oil and gas exploration concessions in the UAE, Oman, N …
  • Wns (Holdings) Limited:企業の戦略・SWOT・財務分析
    Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Syneron Medical Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Syneron Medical Ltd (Syneron Candela), subsidiary of Apax Partners LLP, is a non-surgical aesthetic medical device company. It designs, develops and markets aesthetic medical products. The company products target a range of non-invasive aesthetic medical procedures and address wide range of …
  • Exact Imaging Inc:医療機器:M&Aディール及び事業提携情報
    Summary Exact Imaging Inc (Exact Imaging) formerly Imagistx Inc, is a provider of high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies for prostate cancer analysis. The company’s ExactVu micro-ultrasound platform operates high resolution conventional and biopsy tra …
  • Compuware Corp:企業の戦略・SWOT・財務分析
    Compuware Corp - Strategy, SWOT and Corporate Finance Report Summary Compuware Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Monogram Biosciences Inc:企業の戦略的SWOT分析
    Monogram Biosciences Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Samba Private Banking
    Samba Private Banking - Strategy, SWOT and Corporate Finance Report Summary Samba Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • E-CO Energi Holding AS-エネルギー分野:企業M&A・提携分析
    Summary E-CO Energi Holding AS (E-CO Energi) owned by the City of Oslo is an energy company. It owns, operates and develops hydroelectric plants. The company is the second largest hydropower producer in Norway. E-CO Energi also carries out the business development in energy and related fields. The c …
  • TonenGeneral Sekiyu K.K. (5012)-石油・ガス分野:企業M&A・提携分析
    Summary TonenGeneral Sekiyu K.K. (TonenGeneral) is an energy company that imports, refines and processes crude oil. It also manufactures, distributes and markets petroleum and petrochemical products. The company’s product portfolio includes lubricants, naphtha, sulphur, kerosene, hydrocarbon resin, …
  • Brookfield Renewable Energy Partners LP (BEP.UN):企業の財務・戦略的SWOT分析
    Brookfield Renewable Energy Partners LP (BEP.UN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Bell Helicopter Textron Inc.:企業の戦略・SWOT・財務情報
    Bell Helicopter Textron Inc. - Strategy, SWOT and Corporate Finance Report Summary Bell Helicopter Textron Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • YTL Power International Bhd (YTLPOWR):企業の財務・戦略的SWOT分析
    YTL Power International Bhd (YTLPOWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • The Walter and Eliza Hall Institute of Medical Research-製薬・医療分野:企業M&A・提携分析
    Summary The Walter and Eliza Hall Institute of Medical Research (WEHI), a subsidiary of Melbourne Medical School The University of Melbourne is a medical research institute that conducts clinical research, and offers educational and contract research services. The institute develops therapeutics for …
  • Tieto Corp (TIETO):企業の財務・戦略的SWOT分析
    Tieto Corp (TIETO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Lee Enterprises, Inc. (LEE):企業の財務・戦略的SWOT分析
    Lee Enterprises, Inc. (LEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Evine Live Inc.
    Evine Live Inc. - Strategy, SWOT and Corporate Finance Report Summary Evine Live Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Qliance Medical Management Inc-製薬・医療分野:企業M&A・提携分析
    Summary Qliance Medical Management Inc (QMMI), a subsidiary of Qliance Medical Group is a healthcare service provider that provides primary and preventive care services. The company offers services such as health and wellness, chronic condition management, specialist care coordination, urgent care, …
  • Teekay Corp (TK):企業の財務・戦略的SWOT分析
    Teekay Corp (TK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vectura Group Plc (VEC):医療機器:M&Aディール及び事業提携情報
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • Fiesta Mart LLC:企業の戦略的SWOT分析
    Fiesta Mart LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆